SelectQuote Faces NYSE Compliance Issue as Stock Price Falls Below $1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy SLQT?
SelectQuote announced that the company received a notice from the New York Stock Exchange indicating that the company is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock was less than $1.00 per share over a consecutive 30 trading-day period. The company has notified the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard. The company can regain compliance at any time within the six-month cure period following receipt of the Notice if, on the last trading day of any calendar month during the cure period, the company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLQT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLQT
Wall Street analysts forecast SLQT stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.593
Low
5.00
Averages
6.00
High
7.00
Current: 0.593
Low
5.00
Averages
6.00
High
7.00
About SLQT
SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SelectQuote Faces Delisting Risk as Share Price Falls Below $1
- Delisting Notice: SelectQuote received a notice from the New York Stock Exchange for failing to meet continued listing standards as its average share price fell below $1 for 30 consecutive trading days, indicating poor market performance that could undermine investor confidence.
- Compliance Plan: The company intends to regain compliance within the six-month cure period by lifting its share price, demonstrating its commitment to adhering to market regulations and rebuilding investor trust.
- Trading Continuity: Despite the delisting risk, SelectQuote stated that its stock will continue to trade on the NYSE during the cure period, indicating the company's efforts to maintain market activity and liquidity.
- Future Outlook: SelectQuote is also facing a $40 million financial headwind and has lowered its 2026 guidance, although it targets a 20%+ EBITDA margin and $25–35 million in operating cash flow, reflecting strategic goals amid adversity.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether SelectQuote, Inc. executives breached their fiduciary duties to shareholders, with allegations including failure to disclose the company's direction of Medicare beneficiaries to unsuitable insurance plans, potentially harming shareholder interests.
- Misconduct Allegations: The lawsuit claims that SelectQuote improperly steered Medicare beneficiaries towards certain insurers while receiving illegal kickbacks, indicating serious compliance issues that could expose the company to legal sanctions.
- Increased Compliance Risks: SelectQuote's failure to adhere to applicable laws and regulations may lead to regulatory and legal sanctions, particularly concerning potential violations of the False Claims Act, which could negatively impact the company's reputation and financial health.
- Shareholder Interests at Risk: The executives' actions have resulted in materially misleading positive statements about the company's business prospects, putting shareholders at risk of investment losses, prompting Kuehn Law to urge affected shareholders to contact them promptly to protect their rights.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations including the failure to disclose the company's practice of directing Medicare beneficiaries to unsuitable insurance plans, harming shareholder interests.
- False Statement Allegations: According to a federal securities lawsuit, SelectQuote is accused of failing to provide unbiased comparisons of Medicare Advantage plans and prioritizing its own interests when recommending insurers, potentially facing legal and regulatory sanctions.
- Illegal Kickback Issues: SelectQuote is alleged to have accepted illegal kickbacks to steer Medicare beneficiaries towards specific insurers, thereby limiting enrollment in competitors' plans, which severely impacts the company's compliance and reputation.
- Potential Legal Consequences: Due to these actions, SelectQuote may have violated the False Claims Act, and positive statements regarding the company's operations and prospects are deemed misleading, potentially exposing shareholders to significant financial risks.
See More
SelectQuote Launches Local Franchise Initiative to Expand Insurance Distribution
- Franchise Expansion: SelectQuote has launched the SelectQuote Local initiative, leveraging its industry-leading marketing and technology capabilities to offer Medicare insurance products through a franchise model, thereby enhancing consumer engagement and expanding market share.
- Business Growth Opportunity: Franchise owners can purchase rights to operate in specific regions, providing them with an attractive business opportunity while creating new growth potential for SelectQuote, which is expected to enhance the company's competitiveness in the Medicare insurance sector.
- Financial Benefits: SelectQuote Local is anticipated to drive scale in the insurance distribution business with low capital investment, generating recurring royalty income that enhances cash returns for shareholders, while complementing the growth of the SelectRx pharmacy business.
- Market Positioning Advantage: With over four decades of experience in insurance brokerage, SelectQuote has optimized its marketing and customer service, and the launch of SelectQuote Local will further solidify its leadership position in the Medicare insurance market, addressing the growing demand for senior insurance products.
See More
SelectQuote Reports Strong Q2 2026 Earnings Amid Guidance Cuts
- Strong Financial Performance: SelectQuote reported Q2 revenue of $537 million, a 12% year-over-year increase, with the Healthcare Services segment growing 26%, reflecting robust demand and execution in the senior market.
- Record EBITDA Margins: The company achieved a near-record EBITDA margin of 39% in its Senior division, despite facing budget cuts from PBM and carrier partners, indicating strong profitability resilience.
- Credit Facility Expansion: SelectQuote announced a new $415 million credit facility extending debt maturities to 2031, providing greater financial flexibility to support ongoing profitable growth initiatives.
- Revised Financial Guidance: While management remains confident in long-term targets, the fiscal 2026 revenue guidance has been lowered to a range of $1.61 billion to $1.71 billion due to PBM and carrier budget cuts, highlighting short-term market challenges.
See More
SelectQuote Q2 Earnings Exceed Expectations
- Earnings Beat: SelectQuote reported Q2 GAAP EPS of $0.26, exceeding expectations by $0.05, indicating strong profitability and boosting investor confidence in the company's financial health.
- Revenue Growth: The company achieved revenue of $537.1 million, an 11.6% year-over-year increase, surpassing market expectations by $6.37 million, reflecting SelectQuote's competitive position and driving overall business growth.
- Future Guidance: SelectQuote's guidance for fiscal year 2026 projects revenue between $1.61 billion and $1.71 billion, with adjusted EBITDA expected to range from $90 million to $100 million, showcasing the company's confidence in future growth and strategic planning.
- Financing Support: The company secured a $415 million credit facility, extending debt maturity to 2031, which will provide greater financial flexibility and support its long-term growth strategy.
See More
SelectQuote Faces Delisting Risk as Share Price Falls Below $1
- Delisting Notice: SelectQuote received a notice from the New York Stock Exchange for failing to meet continued listing standards as its average share price fell below $1 for 30 consecutive trading days, indicating poor market performance that could undermine investor confidence.
- Compliance Plan: The company intends to regain compliance within the six-month cure period by lifting its share price, demonstrating its commitment to adhering to market regulations and rebuilding investor trust.
- Trading Continuity: Despite the delisting risk, SelectQuote stated that its stock will continue to trade on the NYSE during the cure period, indicating the company's efforts to maintain market activity and liquidity.
- Future Outlook: SelectQuote is also facing a $40 million financial headwind and has lowered its 2026 guidance, although it targets a 20%+ EBITDA margin and $25–35 million in operating cash flow, reflecting strategic goals amid adversity.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether SelectQuote, Inc. executives breached their fiduciary duties to shareholders, with allegations including failure to disclose the company's direction of Medicare beneficiaries to unsuitable insurance plans, potentially harming shareholder interests.
- Misconduct Allegations: The lawsuit claims that SelectQuote improperly steered Medicare beneficiaries towards certain insurers while receiving illegal kickbacks, indicating serious compliance issues that could expose the company to legal sanctions.
- Increased Compliance Risks: SelectQuote's failure to adhere to applicable laws and regulations may lead to regulatory and legal sanctions, particularly concerning potential violations of the False Claims Act, which could negatively impact the company's reputation and financial health.
- Shareholder Interests at Risk: The executives' actions have resulted in materially misleading positive statements about the company's business prospects, putting shareholders at risk of investment losses, prompting Kuehn Law to urge affected shareholders to contact them promptly to protect their rights.
See More
SelectQuote Executives Allegedly Breached Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations including the failure to disclose the company's practice of directing Medicare beneficiaries to unsuitable insurance plans, harming shareholder interests.
- False Statement Allegations: According to a federal securities lawsuit, SelectQuote is accused of failing to provide unbiased comparisons of Medicare Advantage plans and prioritizing its own interests when recommending insurers, potentially facing legal and regulatory sanctions.
- Illegal Kickback Issues: SelectQuote is alleged to have accepted illegal kickbacks to steer Medicare beneficiaries towards specific insurers, thereby limiting enrollment in competitors' plans, which severely impacts the company's compliance and reputation.
- Potential Legal Consequences: Due to these actions, SelectQuote may have violated the False Claims Act, and positive statements regarding the company's operations and prospects are deemed misleading, potentially exposing shareholders to significant financial risks.
See More
SelectQuote Launches Local Franchise Initiative to Expand Insurance Distribution
- Franchise Expansion: SelectQuote has launched the SelectQuote Local initiative, leveraging its industry-leading marketing and technology capabilities to offer Medicare insurance products through a franchise model, thereby enhancing consumer engagement and expanding market share.
- Business Growth Opportunity: Franchise owners can purchase rights to operate in specific regions, providing them with an attractive business opportunity while creating new growth potential for SelectQuote, which is expected to enhance the company's competitiveness in the Medicare insurance sector.
- Financial Benefits: SelectQuote Local is anticipated to drive scale in the insurance distribution business with low capital investment, generating recurring royalty income that enhances cash returns for shareholders, while complementing the growth of the SelectRx pharmacy business.
- Market Positioning Advantage: With over four decades of experience in insurance brokerage, SelectQuote has optimized its marketing and customer service, and the launch of SelectQuote Local will further solidify its leadership position in the Medicare insurance market, addressing the growing demand for senior insurance products.
See More
SelectQuote Reports Strong Q2 2026 Earnings Amid Guidance Cuts
- Strong Financial Performance: SelectQuote reported Q2 revenue of $537 million, a 12% year-over-year increase, with the Healthcare Services segment growing 26%, reflecting robust demand and execution in the senior market.
- Record EBITDA Margins: The company achieved a near-record EBITDA margin of 39% in its Senior division, despite facing budget cuts from PBM and carrier partners, indicating strong profitability resilience.
- Credit Facility Expansion: SelectQuote announced a new $415 million credit facility extending debt maturities to 2031, providing greater financial flexibility to support ongoing profitable growth initiatives.
- Revised Financial Guidance: While management remains confident in long-term targets, the fiscal 2026 revenue guidance has been lowered to a range of $1.61 billion to $1.71 billion due to PBM and carrier budget cuts, highlighting short-term market challenges.
See More
SelectQuote Q2 Earnings Exceed Expectations
- Earnings Beat: SelectQuote reported Q2 GAAP EPS of $0.26, exceeding expectations by $0.05, indicating strong profitability and boosting investor confidence in the company's financial health.
- Revenue Growth: The company achieved revenue of $537.1 million, an 11.6% year-over-year increase, surpassing market expectations by $6.37 million, reflecting SelectQuote's competitive position and driving overall business growth.
- Future Guidance: SelectQuote's guidance for fiscal year 2026 projects revenue between $1.61 billion and $1.71 billion, with adjusted EBITDA expected to range from $90 million to $100 million, showcasing the company's confidence in future growth and strategic planning.
- Financing Support: The company secured a $415 million credit facility, extending debt maturity to 2031, which will provide greater financial flexibility and support its long-term growth strategy.
See More
